MeiraGTx submits MAA for botacetigene bota-vec for XLRP

MeiraGTx completed its Marketing Authorisation Application to the EMA for bota-vec, the company's lead gene therapy. This submission, expected in December, along with a BLA to the FDA next year, marks a critical step toward the potential commercial launch of the first commercial product.